Should you buy Cardiff Oncology stock now?
No, the technical signal for Cardiff Oncology is currently SELL. Cardiff Oncology trades at $0.93 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.103 with rising momentum (signal: -0.128); RSI is at 43.5 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $5.21 points to 458.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Cardiff Oncology stock?
The average analyst price target for Cardiff Oncology is $5.21. The current price is $0.93, which gives an upside of 458.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $4.69 and $5.73.
Is Cardiff Oncology a dividend stock?
No, Cardiff Oncology does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Cardiff Oncology stock?
Cardiff Oncology is rated as a stock with extreme risk. the annual standard deviation is 83.4%, which classifies the stock as extreme risk.
Is Cardiff Oncology overvalued?
No, Cardiff Oncology is considered undervalued based on the analyst price target (458.0% upside). Cardiff Oncology has the following valuation ratios: a P/S ratio of 137.6, a P/B ratio of 1.9. The analyst price target suggests that the stock is undervalued by 458.0%.
Is Cardiff Oncology overbought?
No, Cardiff Oncology is not overbought. RSI is at 43.5 (neutral zone). The technical indicators show: RSI is at 43.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.4% below the 20-day average (short-term downtrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Cardiff Oncology earnings report?
The date of the next earnings report for Cardiff Oncology has not been published yet. Check the company's investor calendar for updates.
Is Cardiff Oncology shorted?
Yes, Cardiff Oncology is shorted with 18.1% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Cardiff Oncology stock?
Yes, insiders are net buyers of Cardiff Oncology – they are buying more shares than they are selling. Over the last 3 months, insiders have made 4 purchases and 0 sales. On a net basis, 1,120,098 $ worth of shares were bought. Across the last 20 reported transactions, the split is 20 purchases and 0 sales, with a net 3,943,811 $ bought. Active buyers include PACE GARY W, Mohindru Mani, Gary W Pace and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Cardiff Oncology a good stock?
Based on our total score, Cardiff Oncology is rated as a disastrous stock with a total score of 9 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 17/100, Quality: 6/100, Momentum: 4/100. In addition: analysts see 458.0% upside to the price target; technical signal: Strong Sell. Whether Cardiff Oncology is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Cardiff Oncology stock?
The outlook for Cardiff Oncology based on current data: the average analyst price target is $5.21 (+458.0%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Cardiff Oncology stock falling?
Cardiff Oncology is falling right now. The technical indicators show: the price is 2.4% below the 20-day average; short interest is 18.1% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Cardiff Oncology go?
The average analyst price target for Cardiff Oncology is $5.21, which corresponds to a potential gain of 458.0% from the current price of $0.93. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Cardiff Oncology fall?
We lack enough history to give a specific floor for Cardiff Oncology. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Cardiff Oncology do?
Cardiff Oncology driver en biotekvirksomhed, der udvikler nye behandlinger mod forskellige kræftformer. Deres hovedfokus er på lægemiddelkandidaten *onvansertib*, som er en oral hæmmer. Den bruger de til at behandle en række solide tumorer og blodsygdomme, primært aggressiv ta... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Cardiff Oncology as an investment.
Did Cardiff Oncology raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Cardiff Oncology. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Cardiff Oncology making money or losing money?
We have no current profitability data for Cardiff Oncology. See the latest report in the earnings history above.
Can Cardiff Oncology go bankrupt?
The bankruptcy risk of Cardiff Oncology is rated as elevated. Altman Z2 (a model for assessing financial distress) is -28.54 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 17% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Cardiff Oncology have a lot of debt?
No, Cardiff Oncology has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 17%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
